What is the price target for SELB stock?
12 analysts have analysed SELB and the average price target is 3.57 USD. This implies a price increase of 305.13% is expected in the next year compared to the current price of 0.8812.
SELECTA BIOSCIENCES INC (SELB) Forecast, Price Target & Analyst Ratings
NASDAQ:SELB • US8162121045
Current stock price
0.8812 USD
-0.08 (-8%)
At close:
0.9 USD
+0.02 (+2.13%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SELECTA BIOSCIENCES INC (SELB).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Feb 29, 2024
- Period
- Q3 / 2023
- EPS Estimate
- -$0.06
- Revenue Estimate
- 11.246M
Price Target Details & History
Consensus Price Target and Range
Mean target
$3.57
Upside
+ 305.13%
From current price of $0.88 to mean target of $3.57, Based on 12 analyst forecasts
Low
$1.01
Median
$4.08
High
$5.25
Price Target Revisions
1 Month
0.00%
3 Months
-25.00%
Price Target Summary
12 Wall Street analysts provided a forecast for the next 12 months for SELB. The average price target is 3.57 USD. This implies a price increase of 305.13% is expected in the next year compared to the current price of 0.8812.
The average price target has been revised downward by 25% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
81.67%
SELB was analyzed by 12 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about SELB.
In the previous month the buy percentage consensus was at a similar level.
SELB was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-08-18 | Mizuho | Maintains | Buy -> Buy |
| 2023-08-18 | Needham | Maintains | Buy -> Buy |
| 2023-08-18 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2023-08-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-08 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-05-05 | Needham | Reiterate | Buy |
| 2023-04-13 | Needham | Reiterate | Buy |
| 2023-03-22 | Mizuho | Maintains | Buy |
| 2023-03-22 | HC Wainwright & Co. | Maintains | Buy |
| 2023-03-21 | Needham | Reiterate | Buy |
| 2023-03-03 | Needham | Reiterate | Buy |
| 2023-01-31 | Canaccord Genuity | Maintains | Buy |
| 2022-06-21 | HC Wainwright & Co. | Maintains | Buy |
| 2022-06-14 | Needham | Maintains | Buy |
| 2022-06-06 | SVB Leerink | Initiate | Outperform |
| 2022-05-06 | Needham | Maintains | Buy |
| 2021-11-01 | Needham | Maintains | Buy |
| 2021-06-15 | BTIG | Initiate | Buy |
| 2021-03-12 | William Blair | Upgrade | Market Perform -> Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Feb 29, 2024
- Period
- Q3 / 2023
- EPS Estimate
- -$0.06
- Revenue Estimate
- 11.246M
- Revenue Q2Q
- -45.70%
- EPS Q2Q
- -18.99%
- Number of Analysts
- 8
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
60.36%
EPS (1 Month)
0.00%
EPS (3 Months)
43.55%
Next Earnings Summary
SELB is expected to report earnings on 2/29/2024. The consensus EPS estimate for the next earnings is -0.06 USD and the consensus revenue estimate is 11.25M USD.
The next earnings revenue estimate has been revised upward by 60.36% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2023 - 2030
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 16.6M 148.50% | 85.077M 412.51% | 110.777M 30.21% | 29.607M -73.27% | 42.007M 41.88% | 42.584M 1.37% | 45.492M 6.83% | 57.375M 26.12% | 78.438M 36.71% | 87.771M 11.90% | 110.77M 26.20% | |
| EBITDA YoY % growth | -56.09M -8.43% | -3.345M 94.04% | 15.825M 573.09% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -56.82M -8.31% | -4.597M 91.91% | 14.538M 416.25% | -58.744M -504.07% | -27.867M 52.56% | -20.94M 24.86% | -1.785M 91.48% | 6.477M 462.86% | 16.116M 148.82% | 18.309M 13.61% | 33.252M 81.62% | |
| Operating Margin | -342.29% | -5.40% | 13.12% | -198.41% | -66.34% | -49.17% | -3.92% | 11.29% | 20.55% | 20.86% | 30.02% | |
| EPS YoY % growth | -0.69 44.35% | -0.31 55.07% | 0.28 190.32% | -0.36 -228.11% | -0.18 49.76% | -0.12 33.96% | 0.01 108.57% | 0.05 400.00% | 0.06 20.00% | 0.01 -83.33% | 0.10 900.00% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 23 | Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.06 -18.99% | -0.08 -291.25% | -0.04 72.68% | -0.06 12.57% | -0.01 78.57% | -0.06 16.67% |
| Revenue Q2Q % growth | 11.246M -45.70% | 6.979M -58.45% | 14.348M 141.63% | 8.228M 56.75% | 17.408M 54.79% | 8.636M 23.74% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -7.517M -370.11% | -11.087M -30.50% | -3.264M 82.24% | -9.248M 50.38% | -441.997K 94.12% | -10.676M 3.71% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-34.35%
EPS Next 5 Year
-28.87%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-26.62%
Revenue Next 5 Year
-11.85%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
SELECTA BIOSCIENCES INC / SELB Forecast FAQ
What is the next earnings date for SELB stock?
SELECTA BIOSCIENCES INC (SELB) will report earnings on 2024-02-29, after the market close.
What are the consensus estimates for SELECTA BIOSCIENCES INC (SELB) next earnings?
The consensus EPS estimate for the next earnings of SELECTA BIOSCIENCES INC (SELB) is -0.06 USD and the consensus revenue estimate is 11.25M USD.
Can you provide the consensus rating for SELECTA BIOSCIENCES INC stock?
The consensus rating for SELECTA BIOSCIENCES INC (SELB) is 81.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.